These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 19937982

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR, Rolfe M.
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
    Han SW, Won YW, Yi JH, Kim HJ.
    Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
    [Abstract] [Full Text] [Related]

  • 6. Hyperkalemia and renal function during monotherapy and dual renin-angiotensin blockade in the community setting.
    Kurnik D, Vesterman-Landes J, Bialik M, Katzir I, Lomnicky Y, Halkin H, Loebstein R.
    Clin Ther; 2011 Apr; 33(4):456-64. PubMed ID: 21635991
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Hyperkalemia and inhibitors of the renin-angiotensin-aldosterone system.
    Segal A.
    N Engl J Med; 2004 Dec 02; 351(23):2450-1; author reply 2450-1. PubMed ID: 15575066
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials.
    de Denus S, Tardif JC, White M, Bourassa MG, Racine N, Levesque S, Ducharme A.
    Am Heart J; 2006 Oct 02; 152(4):705-12. PubMed ID: 16996842
    [Abstract] [Full Text] [Related]

  • 11. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Raebel MA.
    Cardiovasc Ther; 2012 Jun 02; 30(3):e156-66. PubMed ID: 21883995
    [Abstract] [Full Text] [Related]

  • 12. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.
    Bandak G, Sang Y, Gasparini A, Chang AR, Ballew SH, Evans M, Arnlov J, Lund LH, Inker LA, Coresh J, Carrero JJ, Grams ME.
    J Am Heart Assoc; 2017 Jul 19; 6(7):. PubMed ID: 28724651
    [Abstract] [Full Text] [Related]

  • 13. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system.
    Palmer BF.
    N Engl J Med; 2004 Aug 05; 351(6):585-92. PubMed ID: 15295051
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
    Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B, OPAL-HK Investigators.
    N Engl J Med; 2015 Jan 15; 372(3):211-21. PubMed ID: 25415805
    [Abstract] [Full Text] [Related]

  • 16. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
    Schaefer JA, Gales MA.
    Ann Pharmacother; 2016 Jun 15; 50(6):502-10. PubMed ID: 27009290
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.